Epidermal growth factor receptor (EGFR) mutations are the molecular driver of a subset of
non-small cell lung cancers (NSCLC); tumors that harbor these mutations are often …

Somatic alterations in the epidermal growth factor receptor gene (EGFR) result in aberrant
activation of kinase signaling and occur in∼ 15% of non-small cell lung cancers (NSCLC) …

The discovery of activating epidermal growth factor receptor (EGFR) mutations has opened
up a new era in the development of more effective treatments for patients with non-small cell …

Targeting the epidermal growth factor receptor (EGFR) using tyrosine kinase inhibitors
(TKIs) is highly effective in terms of tumor response rate, survival, and quality of life …

Lung cancer leads cancer-related mortality worldwide. Non-small-cell lung cancer (NSCLC),
the most prevalent subtype of this recalcitrant cancer, is usually diagnosed at advanced …

Globally, lung cancer is the leading cause of cancer-related death. The majority of non-small
cell lung cancer (NSCLC) tumours express epidermal growth factor receptor (EGFR), which …

Patients with advanced non-small-cell lung cancer (NSCLC) and somatic activating
mutations of the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR) …

Epidermal growth factor receptor (EGFR) mutations act as oncogenic drivers in the cellular
signal transduction pathway and induce downstream activation of several key cellular …

EGFR-mutated lung cancers account for a significant subgroup of non–small cell lung
cancers overall. Third-generation EGFR tyrosine kinase inhibitors (TKI) are mutation …

Expression of the EGF receptors (EGFRs) is abnormally high in many types of cancer,
including 25% of lung cancers. Successful treatments target mutations in the EGFR tyrosine …